Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tjark Reblin

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
The Journal of Sexual Medicine|January 21, 2006
Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensivesHermann van Ahlen, Klaus Wahle, Wolfram Kupper, et al.
The Journal of Sexual Medicine|September 1, 2006
Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunctionDan Ziegler, Frank Merfort, Hermann Van Ahlen, et al.
Therapeutic Innovation & Regulatory Science|June 20, 2020
A Framework for Safety Evaluation Throughout the Product Development Life-CycleGreg Ball, Tjark Reblin, James Buchanan, et al.
Drug Safety|January 23, 2016
Social Media Listening for Routine Post-Marketing Safety SurveillanceGregory E Powell, Harry A Seifert, Tjark Reblin, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
The Journal of Sexual Medicine|January 21, 2006
Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensivesHermann van Ahlen, Klaus Wahle, Wolfram Kupper, et al.
The Journal of Sexual Medicine|September 1, 2006
Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunctionDan Ziegler, Frank Merfort, Hermann Van Ahlen, et al.
Therapeutic Innovation & Regulatory Science|June 20, 2020
A Framework for Safety Evaluation Throughout the Product Development Life-CycleGreg Ball, Tjark Reblin, James Buchanan, et al.
Drug Safety|January 23, 2016
Social Media Listening for Routine Post-Marketing Safety SurveillanceGregory E Powell, Harry A Seifert, Tjark Reblin, et al.
Pageof 1